key: cord-1038802-hk6x6mz8
authors: Wu, Yandan; Ding, Yan; Shen, Chuanlai
title: A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus
date: 2022-02-08
journal: Vaccines (Basel)
DOI: 10.3390/vaccines10020257
sha: 2d82a1981e10a10f4f806692a1a8a930670d8b14
doc_id: 1038802
cord_uid: hk6x6mz8

Hepatitis B virus (HBV) infection remains a worldwide health problem and no eradicative therapy is currently available. Host T cell immune responses have crucial influences on the outcome of HBV infection, however the development of therapeutic vaccines, T cell therapies and the clinical evaluation of HBV-specific T cell responses are hampered markedly by the lack of validated T cell epitopes. This review presented a map of T cell epitopes functionally validated from HBV antigens during the past 33 years; the human leukocyte antigen (HLA) supertypes to present these epitopes, and the methods to screen and identify T cell epitopes. To the best of our knowledge, a total of 205 CD8(+) T cell epitopes and 79 CD4(+) T cell epitopes have been defined from HBV antigens by cellular functional experiments thus far, but most are restricted to several common HLA supertypes, such as HLA-A0201, A2402, B0702, DR04, and DR12 molecules. Therefore, the currently defined T cell epitope repertoire cannot cover the major populations with HLA diversity in an indicated geographic region. More researches are needed to dissect a more comprehensive map of T cell epitopes, which covers overall HBV proteome and global patients.

Hepatitis B virus (HBV) infection still disseminates across the world and causes the most common and fatal liver diseases including acute liver failure, chronic hepatitis, liver cirrhosis (LC), and hepatocellular carcinoma (HCC) [1, 2] . Nucleoside analogs and/or interferon are widely utilized antiviral drugs, which can effectively suppress virus replication, decrease serum HBV DNA to undetectable levels, mitigate liver fibrosis, and reduce HCC risk [3] [4] [5] , however cannot eliminate the virus in patients. Recurrence after therapy discontinuation is emerging to be a common etiology of morbidity and mortality in patients with chronic HBV infection [6] .

Numerous researches have demonstrated the important influence of HBV-specific T cell responses on virus clearance [7] , disease progression [8] [9] [10] , antiviral efficacy [11, 12] , and recurrence [13] [14] [15] , particularly the CD8 + T cells, which act as vital effector cells to kill virus-infected hepatocytes and secret cytokines. Patients with acute-resolving HBV infection show robust HBV-specific CD8 + T cell responses, while the patients with chronic HBV infection present a phenomenon termed CD8 + T cell functional exhaustion with multifactorial heterogeneity [9] , and differs depending on the targeted antigen for HLA-A02 restricted epitopes located in the core antigen versus polymerase [16] . Furthermore, the heterogeneity of HBV-specific T cells also responds differently to therapeutic stimuli [17] . Therefore, T cells specific for HBV not only are the potential markers for monitoring the effects of antiviral therapy and predicting the recurrence [18] , but also are the promising modulators in specific immunotherapy. Identifying the T cell epitopes as many as possible from HBV antigens will greatly contribute to the design and development of epitope-based and T cell-based therapies and the detection of host HBV-specific T cell immunity. Although negatively related to persistence to chronic HBV infection in the populations of Africans [26] , Europeans [27] , Koreans [28] and Northwestern Chinese [29] . In addition, HLA-A*33 is closely associated with susceptibility to persisting HBV infection, and HLA-DRB1*13 is closely related to protection against persisting HBV infection in an Iranian population [30] . A*0301 and DRB1*1302 are relevant to viral clearance and B*08 is associated with viral persistence in Caucasians [31] . However, although the correlation between HBV infection and HLA alleles has been studied for several decades, in accordance with what we described in the above review, it often has conflicting results. These variations partly result from host HLA polymorphism in different races and regions [32, 33] . Further studies should be explored in different regions to reduce the heterogeneity of results.

HBV is one of the smallest viruses with a genome length of 3.2 Kb [34] . Its genome contains four open reading frames (ORFs) coding four partially overlapping proteins as displayed in Figure 1 : (1) preS/S ORF encodes large (L), middle (M), and small (S) surface antigens (HBsAg). HBsAg is being widely investigated in clinical fields and quantified as a diagnostic marker of HBV infection as it can reflect the level of covalently closed circular DNA (cccDNA) and intrahepatic HBV DNA in chronic infection [35, 36] . (2) Pre-core/core ORF encodes hepatitis B e antigen (HBeAg), core antigen (HBcAg) or in combination corerelated antigen (HBcrAg). HBeAg has long been advocated as a serum marker for guiding the clinical practice of chronic hepatitis B virus [37, 38] . HBcrAg has been demonstrated more recently as a potential surrogate marker of cccDNA [39] . (3) X ORF encodes HBx antigen (HBxAg), which plays an important role in virus genome transcription and is correlated with liver cancer. The expression of HBxAg in HBV-associated HCC patients is significantly higher than other viral proteins [40] . (4) P ORF encodes the viral DNA polymerase (HBpol), which is responsible for the replication of the viral genome and is an effective target for the therapeutic intervention of chronic HBV infection [41] . Human HBV strains occur in nine genotypes A-I, and its major HBV surface antigen (HBsAg) has several immune protective conformational B cell epitopes a, d or y, w1-4 or r [42] . The entire amino acid sequences of each protein from different genotypes were obtained from the UniProt database and aligned in Figure 2 . The process of T cell epitope identification begins with the selection of candidate epitope peptides. The first strategy is using overlapping peptides (OLPs) spanning the entire proteome or selected antigens of interest (peptide scanning). Chen et al. expanded HBVspecific T cells in vitro by co-culturing the overlapping peptide pools spanning the entire sequence of HBV genotypes B and C and the peripheral blood mononuclear cells (PBMCs) from patients with chronic HBV infection, followed by the detection of T cell response in each co-culture using IFN-γ enzyme-linked immunospot (IFN-γ ELISpot) assay, IFN-γ intracellular staining and flow cytometry [43] . However, peptide scanning is a high-cost and laborious method due to a large amount of OLPs spanning overall HBV proteins. For CD8 + T cell epitopes, HBsAg, HBeAg, HBx and HBpol contain 131, 68, 49, and 279 OLPs, respectively, when overlapping 6 amino acids in each 9-mer peptide. An alternative strategy is to focus on the in silico predicted T cell epitopes binding to the indicated HLA supertypes as calculated by multiple epitope prediction tools and algorithms. Brinck-Jensen et al. predicted 20 HBV-specific epitopes using combined in silico methods and evaluated for the immunogenicity of these epitopes through exposure to patients' PBMCs by IFN-γ ELISpot [44] . More recently, a similar in silico approach was also employed to assess all previously verified HBx-and HBpol-derived epitopes and to predict novel HLA-binding peptides for 6 HLA supertypes. Then, a part of reported epitopes were chosen for experimental validation. A total of 13 HLA binders derived from HBx and 33 binders from HBpol were described across HLA subtypes by this strategy [45] . Predicted epitopes are based on the indicated HLA restrictions and limit the number of research objects with diverse HLA subtypes to a reasonable range, yet the inaccuracy of theoretical prediction may omit some real-world epitopes.

The methodologies to validate the immunogenicity of candidate epitope peptides have been improved remarkably over the last two decades. Different assays are utilized for the detection of peptide-induced T cell response or peptide-specific T cells with individual advantages and disadvantages in terms of practicability, cost, sensitivity, function evaluation. The following approaches are currently widely used, such as cytotoxicity assay, proliferation assay, intracellular cytokine staining (ICS), ELISpot/FluoroSpot, and peptide-MHC multimers staining (tetramers, pentamers, or dextramers). The cytotoxicity assay was initially performed to validate CD8 + T cell epitopes by co-culturing patients' PBMCs with target cells labeled with Chromium-51, after the PBMCs were stimulated by the indicated candidate epitope peptides [46] . Additionally, lymphocyte proliferation assay is mostly applied to CD4 + T cell epitopes validation. The PBMCs from HBV-infected or HBV-vaccinated individuals were co-cultured with HBV-derived peptides for several days and 3 H-thymidine pulses were administered eventually followed by quantifying the incorporated radioactivity [47] . One more common approach currently utilized is ICS or ELISpot/FluoroSpot. Patient's PBMCs are in vitro or ex vivo stimulated with the candidate epitope peptides and simultaneously cytokine release is blocked followed by ICS and flow cytometry to define whether CD4 + T cells or CD8 + T cells activation [48] . The ELISpot or FluoroSpot technology enables the detection of single activated cells among one million PBMCs. The accuracy, sensitivity, reproducibility and durability have led to its widespread applications in researches and the broad prospects in the clinical detection of antigen-specific T cells [49, 50] . An issue encountered with ELISpot, FluoroSpot, ICS, and related assays is that they may ignore T cells that produce different cytokines or trace cytokines during the window of time of the assay (e.g., Follicular helper CD4 + T cells generally produce very low amounts of cytokines). Peptide-MHC tetramer staining has been the gold standard to quantify antigen-specific T cells with high sensitivity and precision, thus is often used to identify T cell epitopes in many researches. However, the preparation of peptide-MHC tetramers or multimers is high-cost, complicated, and timeconsumption [51, 52] . A pioneering study focused on all possible peptides of the entire HBV genome and 484 unique HLA-A1101-restricted epitopes predicted by NetMHC algorithms were validated using mass cytometry and multiplex peptide-tetramers staining [53] . Many researchers also have established a transgenic mouse model to map HLA-restricted epi-topes. Ru et al. developed and immunized HLA-A2/DP4 mice with epitopes derived from HBsAg to identify four new HLA-DP4-restricted epitopes [54] . Besides cellular functional experiments, peptide-HLA molecule binding and stabilization assays were commonly used to identify epitopes. Pan et al. defined 16 HBV epitopes by analyzing the different binding affinities of candidate epitope peptides with HLA-A3303 using RMA-S cells binding and stability assay. More recently, Ferretti et al. used a high-throughput genome-wide screening technology to identify the target cells expressing candidate epitopes productively recognized by T cells (T-Scan) and determined 29 epitopes in SARS-CoV-2 for the six most prevalent HLA types [55] . Chikata et al. employed immunocapture and liquid chromatography mass spectrometry (LC-MS) subsequent to pre-treatment of the target protein to disrupt its three-dimensional structure to characterize HIV-1 epitope peptides on a large scale presented by HLA-C1202 [56] . A variety of epitope assay strategies have been utilized with their own features and potential. Table 1 collected the CD8 + T cell epitopes and CD4 + T cell epitopes defined from HBV proteome during the past 33 years and displayed their HLA restrictions and the methods used to validate their immunogenicity. Notably, we performed manual management in this review, only the epitopes of 8-14 or 12-25 amino acids in length presented by HLA class I molecules or class II molecules are displayed since they reflect the standard size of the peptide-binding groove of HLA molecules. According to the previous report, if the epitope peptides are too short or long, the experiment tends to represent false positives instead of the result caused by the binding of peptide and HLA molecule [57] .

Overall, 82 and 19 studies reported the epitopes presented by HLA class I molecules and class II molecules, respectively, and totally contained 284 unique epitopes including 205 CD8 + T cell epitopes and 79 CD4 + T cell epitopes (Table 1) . Of these, 121 (59.0%) CD8 + T cell epitopes are restricted by HLA-A0201, A2402 or B0702 ( Figure 3A ), which are common supertypes in Caucasians and less predominant in Asia and Africa [58, 59] . The remainder are restricted mainly by 12 HLA-A, 5 HLA-B and 1 HLA-C supertypes. For the CD4 + T cell epitopes, the majority of currently described restrictions apply to 8 DRB1 supertypes ( Figure 3B ). The cumulative frequency of the HLA-A supertypes described in Figure 3A was highest in Europe (66.6%), followed by Asia (53.1%), Africa (50.7%), and North America (52.3%) while the HLA-B supertypes showed an accumulative frequency of 32.7% in Europe, 20.1% in Asia, 19.2% in Africa and 18.8% in North America. The DRB1 supertypes in Figure 3B displayed little difference in the cumulative gene frequency in Europe (30.5%), Asia (32.2%), Africa (31.1%) and North America (34.1%). (Data from http://www.allelefrequencies.net/, assessed on 11 November 2021). Obviously, the 284 validated T cell epitopes of HBV cannot cover the major populations in an indicated geographic region. More T cell epitopes restricted by more HLA supertypes are urgently needed. Further efforts are required to identify more T cell epitopes restricted to the regional prevalent HLA supertypes, especially for the HLA alleles prevalent in Asian populations with a high HBV incidence [59, 60] .

In addition, although the validated T cell epitopes have derived from all HBV proteins, the CD8 + T cell epitopes mainly distribute in HBpol and HBsAg (72%) ( Figure 3C ), while the majority of CD4 + T cell epitopes concentrate in HBeAg and HBsAg (78%) ( Figure 3D ). The biased distribution of epitopes in proteome may be caused partially by the different lengths of proteins (HBpol 843aa, HBsAg 400 aa, HBeAg 212 aa, HBx 154 aa) and the pitfalls of screening methods.

As displayed in the sixth column of Table 1 , most studies used the in silico prediction strategy to screen the candidate CD8 + T cell epitopes (92% of studies) and CD4 + T cells epitopes (63% of studies). Relatively, overlapping peptides were more often used in selecting candidate CD4 + T cell epitopes (7 of 19 studies; 37%) than CD8 + T cell epitopes (7 of 82 studies; 8%), partially due to the lower accuracy and efficacy of predicting HLA class II molecule-binding epitopes as compared with class I molecule-binding epitopes. 

Here, we have taken an effort to present a reliable and updated T cell epitope repertoire of HBV. We summarized the statistics of 205 unique CD8 + T cell epitopes and 79 unique CD4 + T cell epitopes that have been experimentally validated and reported during the past 33 years, corresponding restricting HLA-molecule, and the methods to screen candidate epitopes and validate candidate epitopes. We hope that this review will be used as a tool for the design and development of therapeutic vaccines and T cell detection kits for HBV-infected patients. 

Countdown to 2030: Eliminating hepatitis B disease

HBeAg-negative chronic hepatitis B: Why do I treat my patients with nucleos(t)ide analogues? Liver Int

HBeAg-positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide Analogs? Liver Int

New therapeutic perspectives in HBV: When to stop NAs

Immunobiology of hepatitis B virus infection

Immunopathogenesis of Hepatitis B Virus

Multifactorial heterogeneity of virus-specific T cells and association with the progression of human chronic hepatitis B infection

Genetic and phenotypic difference in CD8+ T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma

Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection

Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection

Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

Clinical Practice Guidelines on the management of hepatitis B virus infection

Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation

Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load

Immunotherapy and therapeutic vaccines for chronic HBV infection

Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions

A systematic review of T-cell epitopes in hepatitis B virus: Identification, genotypic variation and relevance to antiviral therapeutics

Cell Responses in Hepatitis B and C: The (HLA-) A, B, and C of Hepatitis B and C

The ins and outs of MHC class II-mediated antigen processing and presentation

Association of HLA-alleles with the immune regulation of chronic viral infections

Clinical Relevance of HLA Gene Variants in HBV Infection

Hepatitis B virus infection and the immune response: The big questions

Recognition of microorganisms and activation of the immune response

Association between an MHC Class II Allele and Clearance of Hepatitis B Virus in the Gambia

Study of HLA-II antigens in chronic hepatitis C and B

Association between hepatitis B virus infection and HLA-DR type in Korea

Association between hepatitis B virus infection and HLA-DRB1 genotyping in Shaanxi Han patients in northwestern China

Association of human leukocyte antigen polymorphism with outcomes of hepatitis B virus infection

Comprehensive Analysis of Class I and Class II HLA Antigens and Chronic Hepatitis B Virus Infection

Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors

The potential role of HLA-G in the pathogenesis of HBV infection: Immunosuppressive or immunoprotective?

Advances in HBV infection and replication systems in vitro

Quantification of HBsAg: Basic virology for clinical practice

Cuantificación del antígeno de superficie del virus de la hepatitis B: Implicaciones clínicas

HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection

Molecular biology of hepatitis B virus e antigen

Review article: Hepatitis B core-related antigen (HBcrAg): An emerging marker for chronic hepatitis B virus infection

Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma

DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus

Peculiarities in the designations of hepatitis B virus genes, their products, and their antigenic specificities: A potential source of misunderstandings

Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma

Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV

Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength

The Granzyme B ELISPOT assay: An alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity

Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects

Intracellular cytokine detection by fluorescence-activated flow cytometry: Basic principles and recent advances

Multiple Sclerosis

An ELISPOT-Based Assay to Measure HBV-Specific CD8+ T Cell Responses in Immunocompetent Mice

More tricks with tetramers: A practical guide to staining T cells with peptide-MHC multimers

Expansion of CD8+ Cytotoxic T Cells in vitro and in vivo Using MHC Class I

Adaptive immunity in HBV infection

Development of a Humanized HLA-A2.1/DP4 Transgenic Mouse Model and the Use of This Model to Map HLA-DP4-Restricted Epitopes of HBV Envelope Protein

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach

Benchmarking predictions of MHC class I restricted T cell epitopes in a comprehensively studied model system

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus

Requirements for global elimination of hepatitis B: A modelling study

Analysis of epitope-based vaccine candidates against the E antigen of the hepatitis B virus based on the B genotype sequence: An in silico and in vitro approach

Defining CD8+ T Cell Determinants during Human Viral Infection in Populations of Asian Ethnicity

Immunoprevalence and Immunodominance of HLA-Cw*0801-Restricted T Cell Response Targeting the Hepatitis B Virus Envelope Transmembrane Region

Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection

Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection

Frequency and reactivity of antigen-specific T cells were concurrently measured through the combination of artificial antigen-presenting cell

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy

Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection

Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein

Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope

The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis

Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection

The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes

Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis

Peptide-specific CTL induction in HBV-seropositive PBMC by stimulation with peptides in vitro: Novel epitopes identified from chronic carriers

Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses

Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes

Design of TLR2-ligand-synthetic long peptide conjugates for therapeutic vaccination of chronic HBV patients

Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti-CD3 mAb T-cell expansion and "RecycleSpot

Degenerate Immunogenicity of an HLA-A2-Restricted Hepatitis B Virus Nucleocapsid Cytotoxic T-Lymphocyte Epitope That Is Also Presented by HLA-B

Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections

Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable

CD8+ T cells specific to apoptosisassociated epitopes are expanded in patients with chronic HBV infection and fibrosis

Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity

Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides

The L60V Variation in Hepatitis B Virus Core Protein Elicits New Epitope-Specific Cytotoxic T Lymphocytes and Enhances Viral Replication

Identification of HLA-A*0201-restricted CD8+ T-cell epitope C64-72 from hepatitis B virus core protein

Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia

Complex assembly, crystallization and preliminary X-ray crystallographic studies of MHC H-2Kdcomplexed with an HBV-core nonapeptide

Elimination of Immunodominant Epitopes from Multispecific DNA-Based Vaccines Allows Induction of CD8 T Cells That Have a Striking Antiviral Potential

Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*33:03 in peripheral blood mononuclear cells from patients and transgenic mice

Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals

Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy

H-2 Kd-Restricted Hepatitis B Virus-Derived Epitope Whose Specific CD8 + T Lymphocytes Can Produce Gamma Interferon without Cytotoxicity

MHC Class I Presented T Cell Epitopes as Potential Antigens for Therapeutic Vaccine against HBV Chronic Infection

A new unconventional HLA-A2-restricted epitope from HBV core protein elicits antiviral cytotoxic T lymphocytes

HLA-A31-and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis

CD8 + T-Cell Response-Associated Evolution of Hepatitis B Virus Core Protein and Disease Progress

In vivo hierarchy of immunodominant and subdominant HLA-A*0201-restricted T-cell epitopes of HBx antigen of hepatitis B virus

Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes

Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma

Identification and functional studies of HLA-A0201 restricted CTL epitopes in the X protein of hepatitis B virus

Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma

A Whole Recombinant Yeast-Based Therapeutic Vaccine Elicits HBV X, S and Core Specific T Cells in Mice and Activates Human T Cells Recognizing Epitopes Linked to Viral Clearance

Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability

Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: Implications on immunogenicity and immunodominance

Conditional ligands for A sian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases

Human class I supertypes and CTL repertoires extend to chimpanzees

Structural Features of Peptide Analogs of Human Histocompatibility Leukocyte Antigen Class I Epitopes That Are More Potent and Immunogenic than Wild-Type Peptide

A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients

Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire

Identification of novel hepatitis B virus therapeutic vaccine candidates derived from polymerase protein

Cellular Immune Responses to the Hepatitis B Virus Polymerase

Translation from Cryptic Reading Frames of DNA Vaccines Generates an Extended Repertoire of Immunogenic, MHC Class I-Restricted Epitopes

Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines

High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B

Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection

Frequencies of epitope-specific cytotoxic T lymphocytes in active chronic viral hepatitis B infection by using MHC class I peptide tetramers

Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro

Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection

Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling

Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen

Multiepitopic HLA-A*0201-Restricted Immune Response Against Hepatitis B Surface Antigen After DNA-Based Immunization

HBsAg/HLA-A2 transgenic mice: A model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

A mutant HBs antigen (HBsAg)183-191 epitope elicits specific cytotoxic T lymphocytes in acute hepatitis B patients

Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

Selective stimulation of murine cytotoxic T cell and antibody responses by particulate or monomeric hepatitis B virus surface (S) antigen

In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

Cross-Reactive Epitope Specificities of CD8 T Cell Responses Are Induced by Natural Hepatitis B Surface Antigen Variants of Different Hepatitis B Virus Genotypes

HBcAg-specific CD4+CD25+regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection

TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection

Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines

Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen

Characterization of HLA DR13-restricted CD4+ T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B

Inhibitory Phenotype of HBV-Specific CD4+ T-Cells Is Characterized by High PD-1 Expression but Absent Coregulation of Multiple Inhibitory Molecules

In Vivo Inhibition of Anti-Hepatitis B Virus Core Antigen (HBcAg) Immunoglobulin G Production by HBcAg-Specific CD4 + Th1-Type T-Cell Clones in a hu-PBL-NOD/SCID Mouse Model

Characterization of T cell clones specific to a determinant of hepatitis B virus core and e antigens in chronic type B hepatitis: Implication for a T cell mechanism of HBV immunopathogenesis

Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope

Hepatitis B surface antigen presentation and HLA-DRB1*-Lessons from twins and peptide binding studies

In Vitro Binding Analysis of Hepatitis B Virus preS-derived Putative Helper T-cell Epitopes to MHC Class II Molecules Using Stable HLA-DRB1*0405/-DRA*0101 Transfected Cells

Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection

Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine

DRB1*12:01 presents a unique subset of epitopes by preferring aromatics in pocket

Hepatitis B virus (HBV)-derived DRB1*0101-restricted CD4 T-cell epitopes help in the development of HBV-specific CD8+ T cells in vivo